Heidelberg Pharma Shareholders Approve All Agenda Items at 2026 Annual General Meeting, Elect Jack Yefei Ling to Supervisory Board

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), announced that its shareholders approved all management proposals with a large majority of 98.67% to 98.72% at the company’s ordinary virtual Annual General Meeting held on June 23, 2026.

All members of the Management Board and Supervisory Board were formally approved for the 2024/2025 financial year. Shareholders also appointed auditors for the 2025/2026 financial year and approved the remuneration report for the Management Board. Notably, Mr. Jack Yefei Ling was elected as a new member of the Supervisory Board. Additionally, a resolution to amend the Articles of Association to reduce the size of the Supervisory Board from seven to five members was passed. Attendance at the meeting, including postal votes, represented 80.55% of the current capital stock, indicating strong shareholder engagement.

The approval of these items underscores shareholder confidence in Heidelberg Pharma’s strategic direction. The company is pioneering cancer therapies using Amanitin, a toxin derived from the green death cap mushroom, through its proprietary ATAC technology. Their lead candidate, HDP-101 (pamlectabart tismanitin), targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the FDA. Other candidates include HDP-102 for Non-Hodgkin Lymphoma, HDP-103 for metastatic castration-resistant prostate cancer, and HDP-104 for gastrointestinal tumors such as colorectal cancer. These programs, having completed preclinical development, are available for partnering.

The election of Jack Yefei Ling brings new expertise to the Supervisory Board, though his background was not detailed in the release. The reduction in board size from seven to five members may streamline decision-making. For more details on the meeting and voting results, visit https://heidelberg-pharma.com/en/agm. Heidelberg Pharma is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange under the symbol HPHA. More information is available at www.heidelberg-pharma.com.

The implications of this meeting are significant for Heidelberg Pharma’s future. With strong shareholder backing, the company can proceed with its clinical development plans and potential partnerships. The approval of the remuneration report and auditor appointments ensures governance continuity. As Heidelberg Pharma advances its ATAC technology, these decisions reinforce its commitment to developing novel cancer therapies.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Heidelberg Pharma Shareholders Approve All Agenda Items at 2026 Annual General Meeting, Elect Jack Yefei Ling to Supervisory Board.

The post Heidelberg Pharma Shareholders Approve All Agenda Items at 2026 Annual General Meeting, Elect Jack Yefei Ling to Supervisory Board appeared first on citybuzz.